Summary
Johnson & Johnson (JNJ) filed an 8-K on May 1, 2024, primarily to disclose a significant development regarding its talc litigation. The company announced a proposed Plan of Reorganization to comprehensively resolve all current and future ovarian cancer claims in the United States, excluding certain specific claims. This resolution is contingent upon the payment of approximately $6.475 billion (present value) over 25 years, with a nominal value of roughly $8.4 billion. This proposed settlement has a material impact on JNJ's first-quarter 2024 financial results. The company recorded an incremental charge of approximately $2.7 billion, bringing the total reserve for these liabilities to a present value of approximately $11 billion. Consequently, reported GAAP net earnings for Q1 2024 have been reduced from $5.4 billion to $3.3 billion, and reported GAAP EPS has been lowered from $2.20 to $1.34. Importantly, these adjustments do not affect Adjusted Earnings, Adjusted EPS, or Adjusted Operational EPS, which remain unchanged.
Key Highlights
- 1Johnson & Johnson announced a proposed Plan of Reorganization to settle all current and future ovarian cancer claims related to cosmetic talc litigation in the U.S.
- 2The proposed settlement has a present value of approximately $6.475 billion, payable over 25 years (nominal value of approximately $8.4 billion).
- 3An incremental charge of approximately $2.7 billion was recorded for this settlement.
- 4The total reserve for talc litigation liabilities has increased to a present value of approximately $11 billion.
- 5Reported GAAP net earnings for Q1 2024 were reduced from $5.4 billion to $3.3 billion due to this charge.
- 6Reported GAAP EPS for Q1 2024 was reduced from $2.20 to $1.34.
- 7Adjusted Earnings, Adjusted EPS, and Adjusted Operational EPS for Q1 2024 were not impacted by this settlement charge.